THE MERCK MANUAL, Sec. 19, Ch. 265, Childhood Infections This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 19.
THE MERCK MANUAL, Sec. 13, Ch. 161, Parasitic Infections This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 13.
file://C:\Documents%20and%20Settings\pmannle\Desktop\Immunex\pr Amgen completed its acquisition of Immunex Corporation on July 15, 2002.
author: pmannle
file://C:\Documents%20and%20Settings\pmannle\Desktop\Immunex\pr page 2
author: pmannle
Unusual cancers of childhood: Treatment - Health Professional Information [NCI PDQ] - Quest Diagnostics Patient Health Library Unusual cancers of childhood: Treatment - Health Professional Information [NCI PDQ] This information is produced and provided by the National Cancer Institute (NCI).
Rectal cancer: Treatment - Health Professional Information [NCI PDQ] - Quest Diagnostics Patient Health Library Doroshow JH, Multhauf P, Leong L, et al.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Colon cancer: Treatment - Health Professional Information [NCI PDQ] - Quest Diagnostics Patient Health Library Poplin EA, Southwest Oncology Group: Phase III Randomized Study of Bolus Fluorouracil and Leucovorin Calcium with Levamisole vs Continuous Infusion Fluorouracil with Levamisole as Adjuvant Therapy in Patients with High Risk Colon Cancer (Summary Last Modified 04/2000), SWOG-9415, Clinical trial, Closed.
A to Z List - Medication Information Jude Children's Research Hospital.- Disclaimer / Registrations / Copyright Statement - Privacy Policy - Notice of Privacy Practices - Linking Policy - Help A to Z List - Medication Information A to Z List - Medication Information abacavir, lamivudine, zidovudine, trizivir, acyclovir, allopurinol, amifostine, amitriptyline, amlodipine, amoxicillin, clavulanic_acid, augmentin,...
author: St. Jude Children's Research Hospital
St. Jude Publications 2002 J - Z (09/08/03) In order for our site to display correctly you will need a newer version of your web browser.
author: St. Jude Children's Research Hospital
St. Jude Publications 2005 (07/11/05) In order for our site to display correctly you will need a newer version of your web browser.
author: St. Jude Children's Research Hospital
St. Jude Publications 2002 J - Z (09/08/03) In order for our site to display correctly you will need a newer version of your web browser.
author: St. Jude Children's Research Hospital
GNE PrCo Patients were randomized to bolus- IFL (irinotecan 125 mg/ m 2 IV, 5- fluorouracil 500 mg/ m 2 IV, and leucovorin 20 mg/ m 2 IV given once weekly for 4 weeks every 6 weeks) plus placebo (Arm 1), bolus- IFL plus AVASTIN (5 mg/ kg every 2 weeks) (Arm 2), or 5- FU/ LV plus AVASTIN (5 mg/ kg every 2 weeks) (Arm 3).
author: amendoza
Database L L - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.
Folinic Acid calcium salt (Leucovorin) - LKT-F5846 - - For Pricing Information click here and submit your country
August 31, 2003 page 23
August 31, 2003 page 21
http://www.fda.gov/cder/foi/label/2004/125085lbl.pdf Patients were randomized to bolus- IFL (irinotecan 101 125 mg/ m 2 IV, 5- fluorouracil 500 mg/ m 2 IV, and leucovorin 20 mg/ m 2 IV 102 given once weekly for 4 weeks every 6 weeks) plus placebo (Arm 1), 103 bolus- IFL plus AVASTIN (5 mg/ kg every 2 weeks) (Arm 2), or 5- FU/ LV 104 plus AVASTIN (5 mg/ kg every 2 weeks) (Arm 3)
http://www.biotechnav.com/1-04NewsColorBlank.pdf 1 The investment report that gives you the essentials to wisely invest in biotechnology securitiescalcium levels suggests strong efficacy with good tolerability
http://www.biotechnav.com/1-04NewsColorBlank.pdf page 9
CDER Guidance Documents (Issued 8/2000, Posted 8/8/2000) Joint Safety/Efficacy (Multidisciplinary) (Draft) Submitting Marketing Applications According to the ICH/CTD Format: General Considerations (Issued 9/2001, Posted 9/5/2001) [ PDF ] M4 Common Technical Document--Quality: Questions and Answers/Location Issues [ HTML ] or [ PDF ] or [ ] (Issued 9/12/2002, Posted 12/30/2002) Quality Q1E Evaluation of...
http://www.fda.gov/cder/orange/appendix_a.txt ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL INTENSOL,...
Patent and Exclusivity Terms HEPATITIS C U-376 TREATMENT OF INFLUENZA U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS U-378 METHOD FOR TREATING INCONTINENCE U-379 METHOD OF TREATING ONYCHROMYCOSIS U-380 COMBINATIONS OF TAXOL ...
THE MERCK MANUAL, Sec. 19, Ch. 265, Childhood Infections This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 19
THE MERCK MANUAL, Sec. 13, Ch. 161, Parasitic Infections This Publication Is Searchable The Merck Manual of Diagnosis and Therapy--- Section 13
2002 Warning Letters and Untitled Letters to Pharmaceutical Companies Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 2002 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information OfficeLeucovorin, and Amicar - Warning Letter Xanodyne Pharmacal, Inc...
author: STAUFFERP
